Athersys' MultiStem cell therapy improves mortality in respiratory distress syndrome patients

Athersys Inc. (NASDAQ:ATHX) said a 900 million cell dose of IV MultiStem led to a lower mortality rate through 28 days vs. placebo (25%

Read the full 245 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE